ClinicalTrials.Veeva

Menu

Effects of RAS in SZ

S

Shu-Mei Wang

Status

Not yet enrolling

Conditions

Schizophrenia and Schizoaffective Disorder

Treatments

Behavioral: Upper-limb movement training
Behavioral: RAS incorporated in upper-limb movement training

Study type

Interventional

Funder types

Other

Identifiers

NCT07086040
RAS in SZ

Details and patient eligibility

About

The two main groups of medicated patients with schizophrenia (SZ) are those receiving second-generation antipsychotics and those receiving first-generation antipsychotics. The purpose of this research project is to target each patient group to examine effects of rhythmic auditory stimulation (RAS) on upper-limb movements in medicated SZ patients in a 6-month follow-up period.

The main questions of this project are:

  1. Does RAS reduce severity of upper-limb bradykinesia (slow movements) and dyskinesia (repetitive and involuntary movements) after intervention, at 3-month follow-up and 6-month follow-up in SZ patients receiving second-generation antipsychotics? and
  2. Does RAS reduce severity of upper-limb bradykinesia and dyskinesia after intervention, at 3-month follow-up and 6-month follow-up in SZ patients receiving first-generation antipsychotics?

Researchers will compare upper-limb movement training with the aid of RAS to upper-limb movement training without the aid of RAS to see if RAS works to improve upper-limb movements in SZ patients. Participants will:

  1. Undergo an interview and movement tests and fill out questionnaires before and after the movement training program and at 3-month follow-up and 6-month follow-up; and
  2. Receive movement training for 40 minutes per session for a total of 21 sessions.

Enrollment

140 estimated patients

Sex

All

Ages

18 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

[For SZ patients]

Inclusion Criteria:

  • A diagnosis of schizophrenia or schizoaffective disorder
  • Between 18 to 60 years old
  • Keeping the same antipsychotics and the same dosage at least 4 weeks right before joining the study
  • A Edinburgh Handedness Inventory score of > 60
  • A Montreal Cognitive Assessment score of ≥ 24

Exclusion Criteria:

  • Substance abuse or drug abuse
  • Neurological diseases or medical conditions that affect upper-limb movements and hearing
  • Other psychiatric diagnoses in addition to a diagnosis of schizophrenia or schizoaffective disorder

[For healthy participants]

Inclusion Criteria:

  • Between 18 to 60 years old
  • A Edinburgh Handedness Inventory score of > 60
  • A Montreal Cognitive Assessment score of ≥ 24

Exclusion Criteria:

  • Substance abuse or drug abuse
  • Neurological diseases or medical conditions that affect upper-limb movements and hearing
  • Psychiatric diagnoses
  • Taking psychotropic medications
  • Presence of first-degree relatives or siblings with diagnoses of psychiatric diseases.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

140 participants in 4 patient groups

SZ patients receiving second-generation antipsychotics + RAS
Experimental group
Description:
SZ patients receiving second-generation antipsychotics: Provision of upper-limb movement training with the aid of RAS
Treatment:
Behavioral: RAS incorporated in upper-limb movement training
SZ patients receiving second-generation antipsychotics + no RAS
Active Comparator group
Description:
SZ patients receiving second-generation antipsychotics: Provision of upper-limb movement training without the aid of RAS
Treatment:
Behavioral: Upper-limb movement training
SZ patients receiving first-generation antipsychotics + RAS
Experimental group
Description:
SZ patients receiving first-generation antipsychotics: Provision of upper-limb movement training with the aid of RAS
Treatment:
Behavioral: RAS incorporated in upper-limb movement training
SZ patients receiving first-generation antipsychotics + no RAS
Active Comparator group
Description:
SZ patients receiving first-generation antipsychotics: Provision of upper-limb movement training without the aid of RAS
Treatment:
Behavioral: Upper-limb movement training

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems